DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gefitinib
Gefitinib
Multi-Discipline Review
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
BC Cancer Benefit Drug List September 2021
Pulmonary Toxicities of Tyrosine Kinase Inhibitors
Trastuzumab and Paclitaxel in Patients with EGFR Mutated NSCLC That Express HER2 After Progression on EGFR TKI Treatment
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer
Combination of Small-Molecule Kinase Inhibitors and Irinotecan in Cancer Clinical Trials: Efficacy and Safety Considerations
Influence of Gefitinib and Erlotinib on Apoptosis and C-MYC Expression in H23 Lung Cancer Cells
Drugs Against Cancer: Stories of Discovery and the Quest for a Cure
HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: an Antibody–Drug Conjugate for Breast Cancer
CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets
Are Erlotinib and Gefitinib Interchangeable, Opposite
Iressa (Gefitinib)
A Narrative Review of Advances in Treatment and Survival Prognosis of HER2-Positive Malignant Lung Cancers
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Top View
Questions for Review
Gefitinib Efficacy Associated with Multiple Expression of HER Family in Non-Small Cell Lung Cancer
Product Monograph
IRESSA, INN-Gefitinib
Trastuzumab Emtansine Is Active on HER-2 Overexpressing NSCLC Cell
Tyrosine Kinase Inhibitors (Tkis) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects
Lysosomal Sequestration of Sunitinib: a Novel Mechanism of Drug Resistance
Effect of Tyrosine Kinase Inhibitors on Renal Handling of Creatinine By
Cellular Targets of Gefitinib
Comparison of Skin Toxic Effects Associated with Gefitinib, Erlotinib Hydrochloride, Or Afatinib Treatment
Volume 9, Number 2
Gefitinib-Related Gene Signature in Bladder Cancer Cells Identified by a Cdna Microarray
Open Full Page
EGFR and Gastrointestinal Stromal Tumor: an Immunohistochemical and FISH Study of 82 Cases
Antiproliferative Effects of Gefitinib Are Associated with Suppression of E2F-1 Expression and Telomerase Activity
EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines
DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO June 8, 2021
Readministration of EGFR Tyrosine Kinase Inhibitor in Non